司库奇尤单抗治疗银屑病关节炎:随机III期FUTURE 1试验第1年扩展研究至3年的疗效与安全性结果
FUTURE 1研究扩展期评估司库奇尤单抗治疗活动性银屑病关节炎的3年疗效与安全性。460例患者进入扩展研究,308例原随机分配至司库奇尤单抗者纳入疗效评估。至第156周,司库奇尤单抗150 mg组和75 mg组ACR20/50应答率分别为76.8%/54.9%和65.2%/39.0%,无影像学进展比例分别为78.1%和74.8%,安全性与既往一致,无新安全信号。
要点
- 司库奇尤单抗150 mg组ACR20/50应答率分别为76.8%/54.9%,75 mg组分别为65.2%/39.0%(多重插补数据)。
- 至第156周,150 mg组78.1%、75 mg组74.8%的患者无影像学进展(mTSS增加≤0.5,观察数据)。
- 安全性良好,无新安全信号;严重感染暴露调整发生率150 mg组1.7/100患者年、75 mg组1.6/100患者年。
核心结论
- 皮下注射司库奇尤单抗可维持改善活动性银屑病关节炎患者的体征和症状、生活质量及躯体功能,3年内影像学疾病进展率低,耐受性良好且无新安全信号。
研究设计与样本
- FUTURE 1(NCT01892436)为随机III期试验,在2年核心试验后,接受皮下司库奇尤单抗150 mg或75 mg的合格患者进入3年扩展期,报告第156周关键疗效与安全性终点。
- 共460例患者进入扩展研究,其中308例原随机分配至司库奇尤单抗的患者纳入疗效评估。
主要发现
- 至第156周,司库奇尤单抗150 mg组和75 mg组分别有76.8%/54.9%和65.2%/39.0%的患者达到ACR20/50应答(多重插补数据)。
- ACR20应答的维持不受既往抗肿瘤坏死因子暴露影响,生活质量和躯体功能的改善也维持至第156周。
- 影像学结果(观察数据,van der Heijde改良总Sharp评分mTSS)显示,司库奇尤单抗150 mg组78.1%、75 mg组74.8%的患者无影像学进展(mTSS增加≤0.5)。
- 每100患者年的暴露调整发生率(司库奇尤单抗150/75 mg)为:严重感染1.7/1.6,念珠菌感染1.4/0.7,克罗恩病0/0.3,溃疡性结肠炎0/0.3,主要不良心脏事件0.3/0.8。
关键数值与推荐
- ACR20/50应答率:司库奇尤单抗150 mg组76.8%/54.9%,75 mg组65.2%/39.0%(多重插补数据,第156周)。
- 无影像学进展(mTSS增加≤0.5)比例:司库奇尤单抗150 mg组78.1%,75 mg组74.8%(观察数据,第156周)。
- 严重感染暴露调整发生率:司库奇尤单抗150 mg组1.7/100患者年,75 mg组1.6/100患者年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the long-term (3 year) efficacy and safety of secukinumab in patients with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study (NCT01892436). METHODS: Following the 2-year core trial, eligible patients receiving subcutaneous secukinumab 150 or 75 mg entered a 3-year extension phase. Results are presented for key efficacy and safety endpoints at week 156. RESULTS: In total, 460 patients entered the extension study; 308 patients originally randomised to secukinumab were assessed for efficacy. Sustained improvements in all efficacy endpoints were achieved with secukinumab through week 156. Overall, 76.8%/54.9% (secukinumab 150 mg) and 65.2%/39.0% (secukinumab 75 mg) of patients achieved an American College of Rheumatology (ACR) 20/50 response (multiple imputation data); ACR20 responses were sustained irrespective of previous anti-tumour necrosis factor exposure. Improvements in quality of life and physical function were also sustained through week 156. Radiographic results (observed data; van der Heijde modified total Sharp score (mTSS)) showed that 78.1% (secukinumab 150 mg) and 74.8% (secukinumab 75 mg) of patients had no radiographic progression (≤0.5 increase in mTSS) through week 156. Exposure-adjusted incidence rates for selected adverse events per 100 patient-years (secukinumab 150/75 mg) were serious infections (1.7/1.6), Candida infections (1.4/0.7), Crohn's disease (0/0.3), ulcerative colitis (0/0.3) and major adverse cardiac events (0.3/0.8). CONCLUSION: Subcutaneous secukinumab provided sustained improvements in the signs and symptoms, quality of life and physical function of patients with active PsA with low rate of radiographic disease progression through 3 years. Secukinumab was well tolerated with no new safety signals.
引用
- Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018. PMID: 30167329. doi:10.1136/rmdopen-2018-000723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。